Joshua Thurman
Concepts (636)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 46 | 2025 | 316 | 12.010 |
Why?
| | Complement Activation | 68 | 2026 | 411 | 11.390 |
Why?
| | Kidney Diseases | 25 | 2024 | 427 | 8.480 |
Why?
| | Complement Pathway, Alternative | 36 | 2025 | 122 | 6.370 |
Why?
| | Complement Factor H | 19 | 2025 | 80 | 5.800 |
Why?
| | Complement Inactivating Agents | 17 | 2025 | 74 | 4.980 |
Why?
| | Kidney Glomerulus | 18 | 2026 | 128 | 4.930 |
Why?
| | Kidney | 31 | 2023 | 1496 | 3.860 |
Why?
| | Reperfusion Injury | 15 | 2019 | 300 | 3.660 |
Why?
| | Complement Factor B | 25 | 2023 | 106 | 3.610 |
Why?
| | Glomerulonephritis | 9 | 2023 | 45 | 3.540 |
Why?
| | Autoimmune Diseases | 10 | 2025 | 463 | 2.970 |
Why?
| | Immunoglobulin M | 10 | 2025 | 284 | 2.950 |
Why?
| | Complement C3 | 25 | 2023 | 191 | 2.770 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 43 | 2.400 |
Why?
| | Acute Kidney Injury | 13 | 2024 | 866 | 2.320 |
Why?
| | Graft Rejection | 10 | 2025 | 540 | 2.260 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 7 | 2025 | 21 | 2.170 |
Why?
| | Kidney Tubules | 8 | 2024 | 117 | 1.780 |
Why?
| | Receptor, Anaphylatoxin C5a | 7 | 2024 | 35 | 1.680 |
Why?
| | Nephrotic Syndrome | 3 | 2026 | 44 | 1.640 |
Why?
| | Receptors, Complement | 12 | 2026 | 125 | 1.640 |
Why?
| | Lupus Nephritis | 7 | 2021 | 70 | 1.550 |
Why?
| | Endothelial Cells | 8 | 2026 | 870 | 1.550 |
Why?
| | Antibodies | 4 | 2024 | 403 | 1.470 |
Why?
| | Animals | 112 | 2026 | 38109 | 1.460 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 11 | 1.450 |
Why?
| | Kidney Transplantation | 10 | 2025 | 704 | 1.450 |
Why?
| | Annexin A2 | 2 | 2025 | 13 | 1.390 |
Why?
| | Mice | 78 | 2026 | 18365 | 1.380 |
Why?
| | Mice, Knockout | 36 | 2026 | 3125 | 1.360 |
Why?
| | Complement C3d | 10 | 2025 | 67 | 1.360 |
Why?
| | Glomerulonephritis, Membranoproliferative | 6 | 2023 | 25 | 1.330 |
Why?
| | Inflammation | 17 | 2025 | 2880 | 1.300 |
Why?
| | Complement C3b | 4 | 2023 | 30 | 1.290 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 598 | 1.270 |
Why?
| | Epitopes | 8 | 2023 | 485 | 1.240 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 847 | 1.120 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 39 | 1.110 |
Why?
| | Disease Models, Animal | 31 | 2025 | 4569 | 1.100 |
Why?
| | Antibodies, Monoclonal | 17 | 2025 | 1524 | 1.090 |
Why?
| | Epithelial Cells | 10 | 2024 | 1126 | 1.080 |
Why?
| | Mice, Inbred C57BL | 45 | 2025 | 5997 | 1.040 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 15 | 1.040 |
Why?
| | Contrast Media | 4 | 2018 | 488 | 0.960 |
Why?
| | Humans | 108 | 2026 | 144957 | 0.960 |
Why?
| | Complement C5a | 7 | 2024 | 54 | 0.950 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 19 | 0.930 |
Why?
| | Antibodies, Anticardiolipin | 1 | 2025 | 7 | 0.910 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 19 | 0.900 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 75 | 0.880 |
Why?
| | Delayed Graft Function | 1 | 2025 | 46 | 0.880 |
Why?
| | Infliximab | 1 | 2025 | 108 | 0.870 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 370 | 0.870 |
Why?
| | Organ Transplantation | 2 | 2019 | 248 | 0.850 |
Why?
| | Biomarkers | 19 | 2025 | 4275 | 0.800 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 965 | 0.770 |
Why?
| | Nephritis | 2 | 2013 | 22 | 0.760 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 72 | 0.760 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 239 | 0.760 |
Why?
| | Immunoglobulin G | 12 | 2025 | 893 | 0.750 |
Why?
| | Complement Membrane Attack Complex | 7 | 2025 | 38 | 0.740 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 26 | 0.730 |
Why?
| | Tissue Donors | 1 | 2025 | 424 | 0.710 |
Why?
| | Podocytes | 4 | 2026 | 80 | 0.690 |
Why?
| | Precision Medicine | 1 | 2025 | 458 | 0.690 |
Why?
| | Autoantibodies | 11 | 2026 | 1504 | 0.670 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 24 | 0.670 |
Why?
| | Cardiolipins | 1 | 2021 | 82 | 0.670 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3869 | 0.650 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 434 | 0.650 |
Why?
| | Cyclosporine | 3 | 2019 | 265 | 0.590 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 7 | 0.580 |
Why?
| | Biomedical Research | 2 | 2025 | 710 | 0.580 |
Why?
| | Vascular System Injuries | 1 | 2019 | 77 | 0.580 |
Why?
| | Otitis Media | 5 | 2016 | 181 | 0.580 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 80 | 0.570 |
Why?
| | Transplantation, Homologous | 4 | 2025 | 415 | 0.560 |
Why?
| | Complement Factor D | 1 | 2018 | 28 | 0.560 |
Why?
| | Doxorubicin | 5 | 2026 | 397 | 0.550 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 103 | 0.550 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 12 | 0.530 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 444 | 0.510 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 988 | 0.510 |
Why?
| | B-Lymphocytes | 7 | 2022 | 877 | 0.500 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 372 | 0.490 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 653 | 0.490 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 97 | 0.480 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 97 | 0.470 |
Why?
| | Renal Insufficiency | 1 | 2018 | 169 | 0.460 |
Why?
| | Peptide Fragments | 1 | 2019 | 699 | 0.450 |
Why?
| | Graft Survival | 5 | 2025 | 526 | 0.450 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 177 | 0.450 |
Why?
| | Male | 53 | 2026 | 72406 | 0.450 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1253 | 0.430 |
Why?
| | Complement C3a | 4 | 2024 | 40 | 0.430 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 28 | 0.430 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1462 | 0.410 |
Why?
| | Female | 48 | 2026 | 78376 | 0.410 |
Why?
| | Pregnancy Complications | 3 | 2018 | 592 | 0.400 |
Why?
| | Liver Neoplasms | 1 | 2020 | 783 | 0.400 |
Why?
| | Metabolomics | 5 | 2025 | 727 | 0.390 |
Why?
| | Allografts | 3 | 2025 | 150 | 0.390 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 609 | 0.380 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 5 | 0.380 |
Why?
| | Signal Transduction | 11 | 2026 | 5233 | 0.380 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 80 | 0.370 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 275 | 0.360 |
Why?
| | Immunity, Humoral | 1 | 2013 | 120 | 0.360 |
Why?
| | Autoimmunity | 5 | 2022 | 927 | 0.360 |
Why?
| | Molecular Imaging | 1 | 2012 | 58 | 0.360 |
Why?
| | Liver | 2 | 2020 | 1888 | 0.360 |
Why?
| | Complement C1q | 3 | 2014 | 33 | 0.350 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 851 | 0.350 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 126 | 0.340 |
Why?
| | Complement C2 | 2 | 2011 | 8 | 0.340 |
Why?
| | Oxidative Stress | 8 | 2024 | 1339 | 0.340 |
Why?
| | Blotting, Western | 7 | 2016 | 1187 | 0.320 |
Why?
| | CD55 Antigens | 3 | 2020 | 29 | 0.320 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 276 | 0.310 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 25 | 0.310 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 80 | 0.310 |
Why?
| | Cell Membrane | 4 | 2022 | 706 | 0.310 |
Why?
| | Nanoparticles | 2 | 2013 | 520 | 0.310 |
Why?
| | Disease Susceptibility | 2 | 2020 | 348 | 0.310 |
Why?
| | Prognosis | 6 | 2025 | 4293 | 0.300 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 39 | 0.300 |
Why?
| | Glomerular Filtration Rate | 3 | 2025 | 760 | 0.300 |
Why?
| | Adult | 15 | 2026 | 40506 | 0.290 |
Why?
| | Protozoan Proteins | 3 | 1998 | 93 | 0.290 |
Why?
| | Properdin | 2 | 2020 | 9 | 0.280 |
Why?
| | Cytokines | 5 | 2019 | 2065 | 0.280 |
Why?
| | Antibody Specificity | 2 | 2021 | 181 | 0.280 |
Why?
| | Kidney Function Tests | 2 | 2025 | 157 | 0.280 |
Why?
| | Diarrhea | 1 | 2009 | 192 | 0.280 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.270 |
Why?
| | Complement C4 | 5 | 2021 | 26 | 0.270 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 142 | 0.270 |
Why?
| | Uremia | 2 | 2021 | 15 | 0.270 |
Why?
| | Complement C4b-Binding Protein | 2 | 2026 | 4 | 0.270 |
Why?
| | Disease Progression | 6 | 2025 | 2852 | 0.260 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 79 | 0.260 |
Why?
| | Phagocytosis | 4 | 2023 | 299 | 0.260 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.260 |
Why?
| | Cell Line | 7 | 2025 | 2882 | 0.260 |
Why?
| | Tandem Mass Spectrometry | 4 | 2025 | 577 | 0.260 |
Why?
| | Blood Platelets | 2 | 2024 | 400 | 0.260 |
Why?
| | Chemokines, CXC | 1 | 2007 | 68 | 0.250 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 130 | 0.250 |
Why?
| | Adaptive Immunity | 2 | 2019 | 169 | 0.250 |
Why?
| | Cells, Cultured | 6 | 2019 | 4155 | 0.240 |
Why?
| | Immunity, Innate | 7 | 2025 | 846 | 0.240 |
Why?
| | Middle Aged | 13 | 2026 | 35928 | 0.240 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 139 | 0.240 |
Why?
| | Flow Cytometry | 4 | 2022 | 1173 | 0.240 |
Why?
| | Tacrolimus | 3 | 2025 | 196 | 0.240 |
Why?
| | Chemokines | 1 | 2007 | 218 | 0.230 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1718 | 0.230 |
Why?
| | Phosphatidylethanolamines | 1 | 2026 | 76 | 0.230 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 221 | 0.230 |
Why?
| | Immune System Diseases | 1 | 2006 | 39 | 0.230 |
Why?
| | NF-kappa B | 3 | 2016 | 662 | 0.230 |
Why?
| | Protein Binding | 6 | 2019 | 2276 | 0.230 |
Why?
| | Organ Specificity | 3 | 2020 | 313 | 0.230 |
Why?
| | Rats | 9 | 2024 | 5614 | 0.220 |
Why?
| | Pilot Projects | 3 | 2021 | 1890 | 0.220 |
Why?
| | Biopsy | 3 | 2019 | 1077 | 0.220 |
Why?
| | Proteinuria | 4 | 2026 | 102 | 0.220 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 26 | 0.220 |
Why?
| | Caspases | 1 | 2006 | 232 | 0.220 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 24 | 0.220 |
Why?
| | Fetal Death | 1 | 2005 | 58 | 0.220 |
Why?
| | Child | 12 | 2025 | 22657 | 0.220 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 22 | 0.210 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 454 | 0.210 |
Why?
| | Platelet Activation | 1 | 2024 | 104 | 0.200 |
Why?
| | Membrane Glycoproteins | 2 | 2026 | 496 | 0.200 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 41 | 0.200 |
Why?
| | Macular Degeneration | 3 | 2012 | 191 | 0.200 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 11 | 0.200 |
Why?
| | Transplant Recipients | 1 | 2025 | 180 | 0.200 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 37 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 114 | 0.180 |
Why?
| | Ischemia | 3 | 2015 | 421 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2021 | 3608 | 0.180 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 222 | 0.180 |
Why?
| | CD59 Antigens | 3 | 2011 | 20 | 0.180 |
Why?
| | Apoptosis | 2 | 2011 | 2430 | 0.170 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 32 | 0.170 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 80 | 0.170 |
Why?
| | Myoglobin | 1 | 2021 | 12 | 0.170 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 13 | 0.170 |
Why?
| | Immune System | 1 | 2022 | 179 | 0.170 |
Why?
| | Proteomics | 4 | 2018 | 1195 | 0.170 |
Why?
| | Adaptation, Physiological | 1 | 2025 | 570 | 0.170 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 33 | 0.170 |
Why?
| | Glutamic Acid | 1 | 2023 | 251 | 0.170 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 57 | 0.170 |
Why?
| | Frozen Sections | 1 | 2021 | 24 | 0.160 |
Why?
| | Paraffin Embedding | 1 | 2021 | 33 | 0.160 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 477 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2024 | 1980 | 0.160 |
Why?
| | Albuminuria | 2 | 2015 | 190 | 0.160 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 16 | 0.160 |
Why?
| | Formaldehyde | 1 | 2021 | 66 | 0.160 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 24 | 0.160 |
Why?
| | Staining and Labeling | 1 | 2021 | 151 | 0.160 |
Why?
| | Up-Regulation | 3 | 2019 | 852 | 0.160 |
Why?
| | Dendritic Cells | 2 | 2022 | 499 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 171 | 0.150 |
Why?
| | Aged | 8 | 2021 | 25947 | 0.150 |
Why?
| | Lung | 6 | 2024 | 4109 | 0.150 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 15 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 557 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.150 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 194 | 0.150 |
Why?
| | Urinalysis | 1 | 2019 | 80 | 0.150 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1982 | 0.150 |
Why?
| | Treatment Outcome | 3 | 2021 | 11695 | 0.150 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 137 | 0.140 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.140 |
Why?
| | Sepsis | 2 | 2016 | 641 | 0.140 |
Why?
| | Complement C5 | 3 | 2020 | 33 | 0.140 |
Why?
| | Critical Illness | 2 | 2023 | 892 | 0.140 |
Why?
| | North America | 1 | 2019 | 310 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 983 | 0.140 |
Why?
| | Adolescent | 8 | 2025 | 22453 | 0.140 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 14 | 0.140 |
Why?
| | Granulocytes | 2 | 2016 | 80 | 0.140 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2925 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 225 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2020 | 205 | 0.130 |
Why?
| | Organelles | 1 | 1998 | 57 | 0.130 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 23 | 0.130 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 36 | 0.130 |
Why?
| | Gene Expression | 6 | 2017 | 1490 | 0.130 |
Why?
| | Cyclophilins | 1 | 2017 | 40 | 0.130 |
Why?
| | Erythrocytes | 2 | 2020 | 757 | 0.130 |
Why?
| | Brain Injuries | 3 | 2007 | 508 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.130 |
Why?
| | Brachial Artery | 1 | 2018 | 206 | 0.130 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.120 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 863 | 0.120 |
Why?
| | Liraglutide | 1 | 2016 | 32 | 0.120 |
Why?
| | Interferon-beta | 2 | 2007 | 92 | 0.120 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 141 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2022 | 2050 | 0.120 |
Why?
| | Cell Aggregation | 1 | 2016 | 19 | 0.120 |
Why?
| | Bleomycin | 1 | 2018 | 253 | 0.120 |
Why?
| | Sulfonylurea Compounds | 1 | 2016 | 51 | 0.120 |
Why?
| | Insulin, Long-Acting | 1 | 2016 | 65 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 82 | 0.120 |
Why?
| | Blood Pressure | 1 | 2003 | 1769 | 0.120 |
Why?
| | Phenols | 1 | 2017 | 114 | 0.120 |
Why?
| | Ear, Middle | 3 | 2012 | 85 | 0.120 |
Why?
| | Collagen Type VII | 3 | 2018 | 28 | 0.120 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.120 |
Why?
| | Interferon-alpha | 2 | 2007 | 197 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 701 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 291 | 0.120 |
Why?
| | Macrophages | 3 | 2013 | 1511 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1054 | 0.120 |
Why?
| | Carboxypeptidases | 1 | 2015 | 12 | 0.120 |
Why?
| | Mitochondria | 2 | 2024 | 984 | 0.110 |
Why?
| | Immunoprecipitation | 1 | 2016 | 151 | 0.110 |
Why?
| | Inflammation Mediators | 3 | 2019 | 509 | 0.110 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5417 | 0.110 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 337 | 0.110 |
Why?
| | Mucin-5B | 1 | 2018 | 234 | 0.110 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 29 | 0.110 |
Why?
| | Prospective Studies | 4 | 2023 | 7997 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.110 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 8 | 0.110 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.110 |
Why?
| | Analysis of Variance | 2 | 2010 | 1311 | 0.110 |
Why?
| | Vaccinia virus | 1 | 2015 | 34 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.110 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 5 | 0.110 |
Why?
| | Vasodilation | 1 | 2018 | 523 | 0.110 |
Why?
| | Ultrasonography | 1 | 2018 | 770 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1371 | 0.110 |
Why?
| | Edema | 1 | 2015 | 124 | 0.110 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.110 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 115 | 0.100 |
Why?
| | Eustachian Tube | 1 | 2014 | 8 | 0.100 |
Why?
| | Hypertension | 1 | 2003 | 1264 | 0.100 |
Why?
| | Fibroblasts | 1 | 2020 | 1034 | 0.100 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 203 | 0.100 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.100 |
Why?
| | Immunoglobulins | 2 | 2020 | 160 | 0.100 |
Why?
| | Models, Immunological | 2 | 2012 | 100 | 0.100 |
Why?
| | Mast Cells | 1 | 2015 | 146 | 0.100 |
Why?
| | Neutrophils | 2 | 2013 | 1134 | 0.100 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.100 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 72 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 339 | 0.100 |
Why?
| | Cricetulus | 2 | 2010 | 118 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 120 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.100 |
Why?
| | CHO Cells | 2 | 2010 | 171 | 0.100 |
Why?
| | Cricetinae | 2 | 2010 | 304 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1835 | 0.100 |
Why?
| | Serum | 1 | 2013 | 59 | 0.100 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 89 | 0.090 |
Why?
| | Metformin | 1 | 2016 | 319 | 0.090 |
Why?
| | Genetic Variation | 1 | 2018 | 984 | 0.090 |
Why?
| | Recurrence | 1 | 2016 | 1135 | 0.090 |
Why?
| | Acute Disease | 3 | 2014 | 1031 | 0.090 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1126 | 0.090 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.090 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 132 | 0.090 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 173 | 0.090 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 368 | 0.090 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 66 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2016 | 750 | 0.090 |
Why?
| | Rhadinovirus | 1 | 2012 | 20 | 0.090 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 388 | 0.090 |
Why?
| | Amino Acids | 1 | 2016 | 522 | 0.090 |
Why?
| | Sirolimus | 1 | 2014 | 281 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 303 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 49 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 675 | 0.090 |
Why?
| | Skin | 2 | 2015 | 758 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 210 | 0.090 |
Why?
| | Pregnancy | 4 | 2018 | 7191 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 96 | 0.080 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 556 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2011 | 37 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1129 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.080 |
Why?
| | Down-Regulation | 4 | 2020 | 627 | 0.080 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 150 | 0.080 |
Why?
| | Tissue Distribution | 3 | 2019 | 334 | 0.080 |
Why?
| | Risk Factors | 1 | 2025 | 10792 | 0.080 |
Why?
| | Plasma Exchange | 1 | 2010 | 18 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 121 | 0.080 |
Why?
| | Blister | 2 | 2008 | 39 | 0.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 691 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 931 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1495 | 0.080 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 14 | 0.080 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 42 | 0.080 |
Why?
| | Opsonin Proteins | 1 | 2010 | 19 | 0.080 |
Why?
| | Drug Monitoring | 1 | 2013 | 395 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2015 | 1095 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 122 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 86 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 54 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 90 | 0.070 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 371 | 0.070 |
Why?
| | Antibody Formation | 1 | 2010 | 294 | 0.070 |
Why?
| | Osteoarthritis | 1 | 2011 | 196 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 418 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2010 | 247 | 0.070 |
Why?
| | Image Enhancement | 1 | 2010 | 199 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7183 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 384 | 0.070 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1241 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2022 | 2832 | 0.070 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 12 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2738 | 0.070 |
Why?
| | Liver Regeneration | 1 | 2008 | 46 | 0.070 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 35 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.070 |
Why?
| | Cattle | 2 | 2026 | 1000 | 0.060 |
Why?
| | Bacteremia | 1 | 2010 | 221 | 0.060 |
Why?
| | Hemolysis | 2 | 2020 | 243 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1048 | 0.060 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 41 | 0.060 |
Why?
| | Binding Sites | 3 | 2016 | 1331 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2365 | 0.060 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 76 | 0.060 |
Why?
| | Neurons | 2 | 2006 | 1642 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1786 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1389 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 2017 | 541 | 0.060 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.060 |
Why?
| | Young Adult | 2 | 2021 | 14126 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 57 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 196 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2006 | 87 | 0.060 |
Why?
| | Leukocytes | 1 | 2008 | 295 | 0.060 |
Why?
| | Integrin beta1 | 1 | 2026 | 33 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 158 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 157 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 897 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2185 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 7 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 781 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 462 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 32 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2540 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 598 | 0.060 |
Why?
| | Child, Preschool | 3 | 2025 | 11799 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 154 | 0.060 |
Why?
| | Random Allocation | 1 | 2006 | 363 | 0.060 |
Why?
| | Probability | 1 | 2006 | 312 | 0.060 |
Why?
| | Aristolochic Acids | 1 | 2024 | 1 | 0.050 |
Why?
| | Placental Insufficiency | 1 | 2006 | 125 | 0.050 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 24 | 0.050 |
Why?
| | Epitope Mapping | 1 | 2005 | 61 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4099 | 0.050 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 143 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2026 | 178 | 0.050 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.050 |
Why?
| | Lung Transplantation | 1 | 2007 | 338 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2642 | 0.050 |
Why?
| | Schistosomiasis | 1 | 2024 | 49 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3335 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1167 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 194 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 456 | 0.050 |
Why?
| | Myocardium | 1 | 2009 | 939 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 377 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 395 | 0.050 |
Why?
| | Drinking Behavior | 1 | 2003 | 14 | 0.050 |
Why?
| | Compulsive Behavior | 1 | 2003 | 6 | 0.050 |
Why?
| | Lung Injury | 1 | 2006 | 237 | 0.050 |
Why?
| | Brain | 2 | 2006 | 2941 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 33 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 2 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 25 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 53 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 53 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 381 | 0.050 |
Why?
| | Folic Acid | 1 | 2024 | 199 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 223 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 221 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2147 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 67 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 343 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 197 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 737 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 162 | 0.050 |
Why?
| | Energy Metabolism | 2 | 2019 | 936 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 76 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 35 | 0.050 |
Why?
| | Drug Combinations | 2 | 2016 | 392 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 30 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2584 | 0.040 |
Why?
| | Metabolome | 1 | 2025 | 384 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 251 | 0.040 |
Why?
| | Ubiquitination | 1 | 2022 | 118 | 0.040 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 77 | 0.040 |
Why?
| | Phospholipase D | 1 | 2020 | 7 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2022 | 205 | 0.040 |
Why?
| | Cholecalciferol | 1 | 2021 | 60 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 37 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2157 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 587 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 140 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 193 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 364 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 411 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 103 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 108 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 621 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 965 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 23 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 49 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 86 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 198 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 636 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 300 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 161 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 175 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 8 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2020 | 395 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3550 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 336 | 0.030 |
Why?
| | Cyclopentanes | 1 | 1998 | 20 | 0.030 |
Why?
| | Immunity, Active | 1 | 1998 | 8 | 0.030 |
Why?
| | Cell Compartmentation | 1 | 1998 | 54 | 0.030 |
Why?
| | A549 Cells | 1 | 2018 | 75 | 0.030 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 27 | 0.030 |
Why?
| | Parasitemia | 1 | 1998 | 15 | 0.030 |
Why?
| | Aotidae | 1 | 1998 | 10 | 0.030 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 397 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 48 | 0.030 |
Why?
| | Macrolides | 1 | 1998 | 69 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 65 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 400 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 674 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 396 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 138 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 101 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 175 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1217 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 205 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 67 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 69 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 106 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 21 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 430 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 211 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 315 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 127 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 145 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 36 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 916 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Infant | 1 | 2009 | 10039 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 71 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 26 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 84 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 205 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 246 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 241 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 206 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 803 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 268 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 930 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 683 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 37 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 5 | 0.020 |
Why?
| | Pyridones | 1 | 2015 | 199 | 0.020 |
Why?
| | HeLa Cells | 1 | 2015 | 650 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1258 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2931 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 299 | 0.020 |
Why?
| | Sex Factors | 1 | 2019 | 2114 | 0.020 |
Why?
| | Drug Synergism | 1 | 2014 | 357 | 0.020 |
Why?
| | International Cooperation | 1 | 2013 | 198 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2171 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 116 | 0.020 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 63 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 389 | 0.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 157 | 0.020 |
Why?
| | Coinfection | 1 | 2014 | 141 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 84 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 83 | 0.020 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1049 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 25 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 67 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 180 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2029 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2016 | 477 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 190 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 381 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 451 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 174 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 375 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 173 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 672 | 0.020 |
Why?
| | Joints | 1 | 2011 | 107 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 289 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 340 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 465 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 106 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 314 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 198 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 172 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 631 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 404 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 304 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 232 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1385 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 493 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 528 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 260 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 429 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1048 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2118 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1054 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 862 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 23 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 56 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 85 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 168 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 81 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 20 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 138 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1915 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 881 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 380 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2191 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 19 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 62 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 62 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 50 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1423 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 441 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 49 | 0.010 |
Why?
| | fas Receptor | 1 | 2006 | 92 | 0.010 |
Why?
| | Blood Glucose | 1 | 2016 | 2330 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 74 | 0.010 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 112 | 0.010 |
Why?
| | Trachea | 1 | 2007 | 261 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 232 | 0.010 |
Why?
| | Synovial Membrane | 1 | 2006 | 124 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5872 | 0.010 |
Why?
| | Models, Molecular | 1 | 2010 | 1619 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 310 | 0.010 |
Why?
| | Cell Death | 1 | 2006 | 383 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3415 | 0.010 |
Why?
| | Swine | 1 | 2006 | 833 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3164 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 538 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 20 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 31 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 328 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 998 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 167 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1098 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 520 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 780 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 98 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2609 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2032 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1822 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1209 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 1768 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 780 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2884 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 27 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 180 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 403 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|